Research Publications

Švec X, Štorkánová H, Trinh-Minh T, Tran MC, Štorkánová L, Hulejová H, Oreská S, Heřmánková B, Bečvář R, Pavelka K, Vencovský J, Klingelhöfer J, Hussain RI, Hallén J, Šenolt L, Distler JHW, Tomčík M. S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin. Rheumatology (Oxford). 2024 Mar 1;63(3):817-825.

Allanore Y, Khanna D, Smith V, Aringer M, Hoffmann-Vold AM, Kuwana M, Merkel PA, Stock C, Sambevski S, Denton CP; SENSCIS Trial Investigators incl. Distler JHW. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. Rheumatology (Oxford). 2024 Mar 1;63(3):639-647.

Guo M, Liu D, Jiang Y, Chen W, Zhao L, Bao D, Li Y, Distler JHW, Zhu H. Serum metabolomic profiling reveals potential biomarkers in systemic sclerosis. Metabolism. 2023 Jul;144:155587.

Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group incl. Distler JHW. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2023 Sep;75(9):1608-1618.